N-(4,7-dimethyl-2-quinolinyl)guanidine | 503612-31-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-(4,7-dimethyl-2-quinolinyl)guanidine
• 英文别名: Guanidine, (4,7-dimethyl-2-quinolinyl)-；2-(4,7-dimethylquinolin-2-yl)guanidine
• CAS: 503612-31-5
• 化学式: C₁₂H₁₄N₄
• 分子量: 214.27
• InChiKey: CWLWAXGJSWYVAA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  77.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-甲基苯胺 以 N-(6-ethyl-4-methyl-2-quinolinyl)guanidine 为溶剂， 生成 N-(4,7-dimethyl-2-quinolinyl)guanidine
  参考文献：
  名称：

  Compounds for the treatment of pain

  摘要：

  这项发明提供了治疗疼痛、尿失禁和其他由NPFF受体介导的异常的方法，包括向受试者施用在NPFF1受体、NPFF2受体或同时在NPFF1和NPFF2受体上起作用的化学化合物的治疗有效量。

  公开号：

  US20030176314A1

文献信息

• Compounds for the treatment of pain
  申请人：——

  公开号：US20030176314A1

  公开（公告）日：2003-09-18

  This invention provides methods of treating pain, urinary incontinence and other abnormalities mediated by a NPFF receptor, which comprises administering to a subject a therapeutically effective amount of a chemical compound which acts at the NPFF1 receptor, the NPFF2 receptor, or at both the NPFF1 and NPFF2 receptors.

  这项发明提供了治疗疼痛、尿失禁和其他由NPFF受体介导的异常的方法，包括向受试者施用在NPFF1受体、NPFF2受体或同时在NPFF1和NPFF2受体上起作用的化学化合物的治疗有效量。
• Molecules specific for NPFF receptors and uses thereof
  申请人：——

  公开号：US20030144310A1

  公开（公告）日：2003-07-31

  This invention provides a compound having the structure: 1 wherein R1 is straight chained or branched C1-C7 alkyl, hydroxyalkyl, alkoxyalkyl, alkylthioalkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C2-C7 alkenyl or alkynyl; C3-C7 cycloalkyl, monofluorocycloalkyl, or polyfluorocycloalkyl; C5-C7 cycloalkenyl; naphthyl; arylalkyl, heteroarylalkyl, phenyl or heteroaryl, wherein the arylalkyl, heteroarylalkyl, phenyl or heteroaryl is unsubstituted or substituted with one or more of the following substituents: halogen, hydroxy, C1-C6 alkoxy, aryloxy, straight chained or branched C2-C6 alkyl, aryl, heteroaryl, nitro, cyano, C1-C6 alkylthio, substituted or unsubstituted arylalkyl or heteroarylalkyl, —C(═Y)R7, —C(═Y)OR7, —N(R7) 2 , —C(═Y)NR7, —NR7C(═Y)R7 or —N(R7)C(═Y)N(R7) 2 , wherein Y is O or S; wherein R7 is independently H, straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C2-C7 alkenyl or alkynyl; C3-C7 cycloalkyl, monofluorocycloalkyl, or polyfluorocycloalkyl; C5-C7 cycloalkenyl; wherein R2 is —(CH 2 ) n —NH—C(═NH)—NH 2 ; —(CH 2 )n—C(═NH)—NH 2 ; —(CH 2 ) n —N(R7) 2 ; or -J; wherein n is an integer between 1 and 6, and wherein J is any of the following structures: 2 wherein each of R3 and R4 is independently H, straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C2-C7 alkenyl or alkynyl; C3-C7 cycloalkyl, monofluorocycloalkyl, or polyfluorocycloalkyl; or C5-C7 cycloalkenyl; wherein R5 is —OR8 or —N(R8) 2 ; wherein each R8 is independently H, straight chained or branched C1-C7 alkyl, alkoxyalkyl, alkylthioalkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C2-C7 alkenyl or alkynyl; C3-C7 cycloalkyl, monofluorocycloalkyl, or polyfluorocycloalkyl; C5-C7 cycloalkenyl; wherein R6 is arylalkyl, heteroarylalkyl, aryl or heteroaryl, each optionally substituted with one or more of the following substituents: halogen, hydroxy, C1-C6 alkoxy, aryloxy, straight chained or branched C1-C6 alkyl, aryl, heteroaryl, nitro, cyano, C1-C6 alkylthio, substituted or unsubstituted arylalkyl or heteroarylalkyl, —C(═Y)R7, —C(═Y)OR7, —N(R7) 2 , —C(═Y)NR7, —NR7C(═Y)R7 or —N(R7)C(═Y)N(R7) 2 , or a pharmaceutically acceptable salt thereof. This invention also provides a method of treating a lower urinary tract disorder in a subject in need of such treatment comprising administering to the subject an effective amount of any of the aforementioned compounds.

  本发明提供了一种具有以下结构的化合物：1其中，R1是直链或支链C1-C7烷基，羟基烷基，烷氧基烷基，烷硫基烷基，单氟烷基或多氟烷基；直链或支链C2-C7烯基或炔基；C3-C7环烷基，单氟环烷基或多氟环烷基；C5-C7环烯基；萘基；芳基烷基，杂芳基烷基，苯基或杂芳基，其中芳基烷基，杂芳基烷基，苯基或杂芳基未取代或取代有以下一种或多种取代基：卤素，羟基，C1-C6烷氧基，芳氧基，直链或支链C2-C6烷基，芳基，杂芳基，硝基，氰基，C1-C6烷硫基，取代或未取代的芳基烷基或杂芳基烷基，-C(═Y)R7，-C(═Y)OR7，-N(R7)2，-C(═Y)NR7，-NR7C(═Y)R7或-N(R7)C(═Y)N(R7)2，其中Y是O或S；其中R7独立地是H，直链或支链C1-C7烷基，单氟烷基或多氟烷基；直链或支链C2-C7烯基或炔基；C3-C7环烷基，单氟环烷基或多氟环烷基；C5-C7环烯基；其中R2是-(CH2)n-NH-C(═NH)-NH2；-(CH2)n-C(═NH)-NH2；-(CH2)n-N(R7)2；或-J；其中n是1至6之间的整数，其中J是以下任何一种结构：2其中R3和R4各自独立地是H，直链或支链C1-C7烷基，单氟烷基或多氟烷基；直链或支链C2-C7烯基或炔基；C3-C7环烷基，单氟环烷基或多氟环烷基；或C5-C7环烯基；其中R5是-OR8或-N(R8)2；其中每个R8独立地是H，直链或支链C1-C7烷基，烷氧基烷基，烷硫基烷基，单氟烷基或多氟烷基；直链或支链C2-C7烯基或炔基；C3-C7环烷基，单氟环烷基或多氟环烷基；C5-C7环烯基；其中R6是芳基烷基，杂芳基烷基，芳基或杂芳基，每个可选地取代有以下一种或多种取代基：卤素，羟基，C1-C6烷氧基，芳氧基，直链或支链C1-C6烷基，芳基，杂芳基，硝基，氰基，C1-C6烷硫基，取代或未取代的芳基烷基或杂芳基烷基，-C(═Y)R7，-C(═Y)OR7，-N(R7)2，-C(═Y)NR7，-NR7C(═Y)R7或-N(R7)C(═Y)N(R7)2，或其药学上可接受的盐。本发明还提供了一种治疗需要此类治疗的受体下尿路障碍的主题的有效量的任何上述化合物的方法。
• COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND WAKEFULNESS
  申请人：Chow Suk Hen

  公开号：US20150246140A1

  公开（公告）日：2015-09-03

  In some aspects, the invention relates to methods of treating conditions associated with sleep disorders, comprising administering an agent that modulates the activity of a neuropeptide receptor or a neuropeptide receptor ligand. In some aspects, the invention relates to methods of screening agents that modulate the activity of a neuropeptide receptor in an organism, optionally using cells or organisms comprising a genetic modification that affects a neuropeptide signaling pathway. In some aspects, the invention relates to methods of characterizing a condition associated with a sleep disorder comprising sequencing a nucleic acid encoding either a neuropeptide receptor or a neuropeptide receptor ligand and comparing the sequence with a reference sequence.
• [EN] COMPOUNDS FOR THE TREATMENT OF PAIN<br/>[FR] COMPOSES UTILES POUR LE TRAITEMENT DE LA DOULEUR
  申请人：SYNAPTIC PHARMA CORP

  公开号：WO2003026657A1

  公开（公告）日：2003-04-03

  This invention provides methods of treating pain, urinary incontinence and other abnormalities mediated by a NPFF receptor, which comprises administering to a subject a therapeutically effective amount of a chemical compound which acts at the NPFF1 receptor, the NPFF2 receptor, or at both the NPFF1 and NPFF2 receptors.
• [EN] MOLECULES SPECIFIC FOR NPFF RECEPTORS AND USES THEREOF<br/>[FR] MOLECULES SPECIFIQUES DES RECEPTEURS NPFF ET UTILISATIONS DE CES DERNIERES
  申请人：SYNAPTIC PHARMA CORP

  公开号：WO2003026575A2

  公开（公告）日：2003-04-03

  The invention is drawn to compounds that contain a sulfonamide moiety and pharmaceutically acceptable salts thereof. The compounds are used in treating lower urinary tract disorders and pain.